HAPC

Aida Pharmaceuticals is a China-based pharmaceutical company focused on the development, manufacturing, and commercialization of therapeutic products for infectious diseases and oncology. The company's lead commercial product is Etimicin, a proprietary Category 1 aminoglycoside antibiotic used to treat a wide range of bacterial infections in the Chinese market. Aida's research and development pipeline includes several innovative candidates, such as a recombinant human Apo2 ligand (Rh-Apo2l) and an anti-CTLA-4 monoclonal antibody, both aimed at treating various forms of cancer. The company operates through its main subsidiary, Hangzhou Aida Pharmaceutical, and maintains GMP-certified manufacturing facilities in Hangzhou and Changzhou. While its US-listed entity has seen limited activity in recent years, Aida remains an established player in the Chinese pharmaceutical industry.